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Abstract
While great interest in health effects of natural product (NP) including dietary supplements and foods persists, promising preclinical NP research is not consistently
translating into actionable clinical trial (CT) outcomes. Generally considered the
gold standard for assessing safety and efficacy, CTs, especially phase III CTs, are
costly and require rigorous planning to optimize the value of the information obtained. More effective bridging from NP research to CT was the goal of a Septe
mber, 2018 transdisciplinary workshop. Participants emphasized that replicability
and likelihood of successful translation depend on rigor in experimental design, interpretation, and reporting across the continuum of NP research. Discussions spanned
good practices for NP characterization and quality control; use and interpretation
of models (computational through in vivo) with strong clinical predictive validity;
controls for experimental artefacts, especially for in vitro interrogation of bioactivity
and mechanisms of action; rigorous assessment and interpretation of prior research;
transparency in all reporting; and prioritization of research questions. Natural product
clinical trials prioritized based on rigorous, convergent supporting data and current
public health needs are most likely to be informative and ultimately affect public
health. Thoughtful, coordinated implementation of these practices should enhance
the knowledge gained from future NP research.
KEYWORDS
clinical predictive validity, dietary supplements, model systems, rigor and replicability, value of
information
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IN TRO D U C T IO N
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Background

Research on health effects of natural products (NPs) has
often stemmed from traditional use, or from evidence that
higher consumption of plant foods is associated with better health outcomes (see 1 and refs. therein). This research
has resulted in the successful development of many active
ingredient-based pharmaceuticals from NPs. In contrast to
a typical drug development pathway, studies based on traditional uses or epidemiological data rarely begin with a

precise understanding of the active molecules or their molecular mechanisms of action. A growing number of recent
efforts to elucidate the mechanisms of action of traditionally used NPs have reported finding a complex mixture of
bioactive constituents that act at multiple targets.2-5 Perhaps
partly as a result of this still incompletely understood complexity, to date many NIH-supported clinical trials (CTs)a of
complex NPs (NPCTs), in particular the majority of large,
randomized, controlled clinical trials (RCTs), have failed to
reject the “null hypothesis,” that is, they detected no significant difference between the intervention and negative controls.6-8 While CTs that fail to reject their null hypothesis can
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still provide invaluable guidance, the results of such trials
are often met with concerns that different design choices—
whether of product, dose, timing, participant eligibility criteria, outcomes, etc.—might have yielded a substantially
different result. Each interventional trial represents a substantial investment, with well-powered Phase III CTs typically
consuming more than $10 million and many person-years.9,10
Additionally, as time and funds are limited, and participant
pools may also be constrained, a decision to invest in a CT
often precludes pursuing other research questions,11 which
may provide more useful public health-relevant knowledge
than an RCT with an insufficient evidence base.

1.1.1

|

Definitions

NPs were defined as including materials such as animals, marine organisms, plants/botanicals/herbals, macroscopic fungi,
bacteria, probiotics, and minerals, and materials derived from
them, including isolates, extracts, vitamins, and amino acids.
NPs may vary in chemical complexity, ranging from crude to
extensively purified materials, and were considered to include
dietary supplements, certain foods, traditional medicines, and
other products derived from multiple natural sources.
Complex NPs: NP preparations which retain a large number of chemical constituents whose relative concentrations
and chemistry (metabolome composition) reflect the inherent variability of the sources, as opposed to products consisting of a very limited number of highly purified NP-derived
constituents.

1.1.2

|

Challenges to be addressed

For investigation of traditionally used NP, research design
may be complicated by the chemical complexity and inherent variability of the NPs.12-14 The often incomplete and/or
conflicting information on mechanisms of action, appropriate uses, and expected health effects poses challenges for
formulating hypotheses and designing CT. The ready availability of a variety of preparations of similar NPs and their
occurrence in complex matrices such as foods or dietary supplements further increases the challenges for the design, conduct, and interpretation of NPCTs.15-17 The variety of NPs
in the marketplace poses challenges for product selection; in
addition, participants must be monitored for inadvertent or
otherwise unreported exposure to the intervention or components thereof (drop-ins). Here, consistent with the NIH
definition, we use the term CT not only for efficacy trials
but also for any study in humans which assesses NP safety,
bioavailability, pharmacokinetics (PK), pharmacodynamics
(PD), dose-response, mechanisms of action, and biological
markers thereof.

1.2
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Focus and objectives

To discuss good practices for addressing these challenges,
a two-day, public workshop on September 13 and 14, 2018
brought together speakers and attendees across disciplines
and from academia, government, industry, and private practice at the NIH campus in Bethesda, Maryland. Past efforts
to enhance rigor in NP research include the NCCIH Policy
on Natural Product Integrity18 as well as numerous guidance documents addressing identification, reproducibility,
study design, and execution, as well as conflict of interest
issues.6,19-27 As was done for a recent workshop focused on
fatty acids,28 we assemble here relevant prior publications
citing critical or state-of-the-art approaches drawn from a
breadth of NP research and related disciplines, and address
in greater depth NP-related topics that were specific foci of
the workshop.
Reproducibility, replicability, and other critical characteristics of a solid evidential foundation have been variously
defined in different sub-disciplines.29,30 Consistent with the
2019 NASEM Report on Reproducibility and Replicability in
Science,31 this article uses the term reproducibility for “obtaining consistent results using the same input data, computational steps, methods, and code, and conditions of analysis,”
and the term replicability for “obtaining consistent results
across studies aimed at answering the same scientific question, each of which has obtained its own data.”
The workshop was predicated on the premise that adherence
to a well-integrated set of good practices along the continuum
from ethnobotany and epidemiology through basic biomedical
research to CTs should enhance the effectiveness of translation
from preclinical research and early phase CTs to information
usable by consumers, manufacturers, practitioners, research
funders, and other stakeholders. The good practices should also
help reduce premature initiation of Phase III NPCTs, thus reducing instances producing strong grounds for post-trial concerns
about the evidence base for a given trial. This article summarizes and updates the workshop discussions of such practices,
which include those that apply to individual sub-disciplines,
as well as productive combination of approaches across disciplines. The integration of all of these practices, along with the
application of sound inductive reasoning, rigorous, appropriate, and transparent statistical analyses (Table 1),32-36 as well
as targeting an effect size that is significant to clinicians and
consumers37 should increase the replicability and translational
relevance of basic and preclinical NP research. Ultimately, this
will serve to limit resources expended on flawed premises producing irreplicable data,38-40 and to ensure optimal knowledge
gained from every NPCT, regardless of whether the results are
consistent with benefit, harm, or absence of an effect on the
assessed outcome(s).
This review summarizes areas of both consensus and
contention that emerged from the workshop discussions.
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TABLE 1

Highlights of broadly applicable good practices for
enhanced replicability, transparency, and translational relevance of NP
research
1. Models, by definition, differ from the actual subject of interest,
however, when carefully chosen to address a clearly defined experimental question they can provide critical insights.235 Sound
inductive reasoning, including careful consideration of differences between the model and the actual subject of interest, must
be used in interpreting model system outcomes, for example,
response in an experimental model may demonstrate a biologically relevant activity, but does not imply clinical efficacy.
2. Quality control. Ongoing, discipline-appropriate quality control
is critical for all experimental assays and research components,
from NP, through cell lines, microphysiological systems,58 in
silico, and whole-organism models, to CT procedures.
3. Replication is critical: within and across distinct model systems,
with methods based on orthogonal principles, and in multiple
labs. Results that replicate across models, methods, labs, are
more likely to replicate in a CT.
4. Rigor. The same rigorous practices used in CT to avoid bias and
enhance replicability should be applied in hypothesis-testing
experiments that may be used in designing a CT. This includes
randomization of wells/dishes/animals, masking/blinding of
study personnel, and sample size calculations. Exploratory studies merit equally complete and transparent reporting but may
accommodate less stringent procedures.
5. Reporting. Use approaches and venues that support more complete, transparent, and cumulative reporting.
a. Registration: use registered reports and pre-publication registries for preclinical in vivo studies as well as CT, for example,
clinicaltrials.gov and preclinicaltrials.eu. Information needed
to replicate research on complex NPs may go substantially
beyond the intervention characterization required by these
sites, see, for example, nccih.nih.gov/research/policies/natur
alproduct.htm
b. Outlet: publish in journals that do not limit supplemental
information.
c. Publish: exploratory studies (without forcing them into
hypothesis-testing frameworks) and null results of hypothesistesting studies.
d. Openness: curate key information for scientific research in
publicly accessible databases, for example, curatescience.org.

While the workshop focused on approaches to improve
the knowledge gained from future randomized, controlled,
NPCTs, some attendees questioned the appropriateness of
and need for such trials, especially for traditionally used
botanical preparations, arguing that beneficial effects of
such practices cannot be detected in the context of a conventional CT.
Moving from a narrower to a broader and more applied focus, this review begins with good practices for
the application of assays used to elucidate NP bioactive
constituents, and continues through the specification and
characterization of NP interventions, endogenous and
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exogenous factors that may influence the translational relevance of preclinical in vivo models, and the strengths and
weaknesses of a broad range of state-of-the-art models.
Subsequently, the review will address additional factors
that influence the likelihood of successful translation to
humans, including assessment of the supporting research,
and concludes with approaches for evidence-based prioritization of this research. The review is organized into four
main sections:
•
•
•
•

Good practices for preclinical NP studies
NP characteristics critical for replicability
Translational relevance of preclinical NP research
Good practices for moving to NPCTs

Figure 1 provides the graphical overview of the relationships
among the covered topics, and Table 1 highlights broadly applicable good practices. The subsequent tables highlight good
practices from each of the four main sections:
• Table 2 highlights the good practices for the use of in vitro
and in silico models.
• Table 3 highlights the good practices for NP selection, formulation, and characterization.
• Table 4 highlights the good practices for the use of preclinical in vivo models.
• Table 5 highlights the critical considerations in NPCT
design.
• Table 6 highlights the issues to consider in NPCT
decision-making.

2 | GOOD PRACTICES FOR
PRECLINICAL NP STUDIES
2.1 | Optimizing the use of in vitro,
invertebrate, and in silico models and
ethnobotanical approaches
Good practices in model systems (in vitro, invertebrate, in
silico) and in translating from traditional medical systemsb
to clinical research can enhance the replicability and translational relevance of preclinical NP studies. To date, the application of invertebrate model systems and some newer in vitro
models has been very limited in NP research.
The measurement of activity in in vitro assays is a typical
starting point for research on potential clinical application(s)
of a NP. Good practices in proceeding from other starting
points are discussed below. In vitro assays are also commonly
used for monitoring the stability and potency of NPs, as well
as for identifying fractions or components responsible for the
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F I G U R E 1 Critical information for the design, implementation, and interpretation of natural product clinical trials. Elucidating details
(light bulbs) of molecular mechanisms of action prior to initiating a NPCT can help “de-risk” the planned trial by both providing evidence for
the hypothesized outcome and its underlying causes, and supporting the development of methods to test that hypothesis. It is a good practice for
researchers to establish standard procedures for product preparation (A), that are optimized for bioactivities and stability, and methods, preferably
validated, for thorough characterization of product chemistry and stability. Elucidation of the bioactive NP constituents or metabolites (B) is
critical for quality control, for assessing bioavailability, PK and PD, and determining whether minimal effective concentrations of bioactives have
been achieved in plasma or at the targets (C). These data can support the development of methods to test mechanistic hypotheses, for example, by
measuring in vivo engagement of the putative targets, proximate bioactivities, or PD, and/or assessing the relationships between these and (D) the
primary and secondary NPCT outcomes, and any adverse events

assayed bioactivities. The replicability of these assays depends
on many inputs, beginning with the test article, which often
is a chemically complex NP. Good practices to enhance the
replicability of vertebrate cell culture-based assays have been
described elsewhere,38,39,41 as have recommendations for the
use of antibodies.42 The following, therefore, focuses on issues
more specific to the use of NPs in cell-based assays, and on approaches to enhance the translational relevance of those assays.
Data generated by high-throughput screens (HTS) and in
vitro bioactivity assays pose many challenges for interpretation, importantly including their high potential for false
discovery. Small molecule NP constituents and their spontaneous breakdown products and/or metabolites43,44 have
significant potential to generate in vitro assay artefacts via aggregation,45 fluorescence, light absorption, metal chelation,
plasma or intracellular membrane disruption,46,47 protein denaturation, and/or specific and non-specific reactivity with biological nucleophiles (Table 2). For example, HTS and other
in vitro studies of extracts and other preparations derived
from Curcuma longa (turmeric; often improperly designated
as “curcumin”) are susceptible to confounding due to the low

stability44 and high reactivity of the curcuminoids, as well as
the frequent lack of clarity as to the actual composition of
a given preparation.48,49 Workshop speakers emphasized the
need to design and conduct in vitro experiments in ways that
mitigate and/or reveal such artefacts,41,50,51 for example, by
time course and chemical analyses, as well as by comprehensive and transparent reporting of experimental parameters.

2.2

|

In vitro models

In vitro approaches leverage simplified models of more
complex biological systems in the interests of higher
throughput and increased ability to decipher causal mechanisms (Table 1). In vitro models that better reflect the
biology of an intact organism have been developed, taking advantage of advances including the use of primary,
patient-derived cells and stem cells, direct differentiation
of induced pluripotent stem cells, more precise methods of
gene replacement, and identification and quantification
of heterogeneity in vivo and in vitro. In vitro models are
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TABLE 2

Highlights of good practices for the translational
relevance of in vitro models assessing NP bioactivities and
mechanisms of action
1. Artefacts. When using in vitro assays of NP activity, test for
common types of NP assay interference, for example, fluorescence or absorption, membrane disruption, protein denaturation,
and specific and non-specific reactivity with nucleophiles.48
2. Bioavailability. If in vitro activity is observed only at concentrations substantially higher than those achievable in vivo in the
tissue of interest, then the probability of seeing a robust clinical
effect of consuming the NP is likely insufficient to form the
basis for a NPCT.
3. Non-specific molecular mechanism(s) of action. Include controls
for non-classical mechanisms of action such as metal chelation,87
modulation of DNA modifying enzymes, or intercalation into
plasma or subcellular membranes.46,87
4. Biomimetic in vitro models. Consider pros and cons of more
morphologically detailed “3D” models using human-derived
cells. Organoids, “organs-on-a-chip” (OoC), and multi-organ
biomimetic models (eg, human-derived intestine, liver, and
kidney OoC coupled by appropriate microfluidics) can yield
more translationally relevant high-throughput information than
monolayer cell cultures, and are a powerful complement to
preclinical in vivo models.

also increasingly leveraging advances in tissue engineering, microfluidics, and real-time biosensors of physiological processes. These in vitro models range in the extent to
which they mimic in vivo conditions from relatively simple
spheroids,52 through patient tissue-derived organoids, selforganizing stem-cell-based organoids,52,53 single “organs
on chips” (OoC) under flow, and integrated, multi-OoC
microphysiology systems (MPS).54-60 While still relatively
high-throughput, these models from both healthy and
diseased tissues have greater similarity to the chemistry,
three-dimensional structure and component localization,
environment, and possibly genetic stability of an intact organism than classical cell cultures grown on relatively flat
substrates. Moreover, through the use of human-derived
cells, these models may partially address the challenge of
species differences in responses (Table 2).61-64 MPS also
allow targeted assessment of cell-type- or organ-specific
dose responses (Table 4). Some major challenges in the
use of MPS and other complex in vitro systems have recently been addressed, including the development and implementation of metrics for replicability and approaches to
prevent the artefactual binding of hydrophobic molecules
to the devices.59,65 Models incorporating elements of the
human immune system are beginning to be developed.66
However, understanding how to translate results from in
vitro systems such as MPS to CT, for example, into calculated dose ranges remains challenging.
Only those effects observed in vitro at concentrations
achievable in vivo following ingestion, or in systems that
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incorporate upstream components modeling the functions of
the gastrointestinal tract,67 are likely to be clinically relevant
to oral dosing. Activities observed only at higher concentrations than can be obtained following ingestion should not be
over-interpreted in planning CTs of ingested products (Table
2). Notably, many NP constituents show very limited oral
bioavailability. Ex vivo models may be used for extensive
pharmacodynamic characterization of NP, but they do not
fully recapitulate human physiology. For instance, a promising NP candidate in an in vitro cell screening assay may
be metabolized by the liver into an ineffective or even toxic
byproduct.68 In vivo validation of in vitro results remains a
key component of preclinical studies.
Speakers described several approaches to manage the
sometimes limited or conflicting information on NP biological activities and their underlying mechanisms, including determining which NP components and cellular and molecular
targets are required for activity in animals. The application to
chemically complex NPs of agnostic (or non-targeted) in vitro
assays69 combining cutting-edge computational approaches,
optimized mass spectrometric (MS) data collection and
analysis to elucidate chemical composition, and cytological
profiling70,71 now enables the generation of strong and specific hypotheses regarding bioactive NP components and the
mechanisms through which they affect gene expression or cell
phenotype.72-76 Such systems have the ability to interrogate
multiple chemical components and their combinations simultaneously, without purification of individual constituents. This
ability is critical, given accumulating evidence (consistent
with tradition) that multiple chemical constituents in even a
single botanical extract may contribute to bioactivity via distinct or similar molecular mechanisms.77,78 These may include
effects by constituents on each others’ solubility (or other aspects of bioavailability) or toxicity.5,79 These novel, non-targeted platforms also have the advantage of generating strong,
testable mechanism of action hypotheses without requiring
assumptions or prior knowledge regarding those mechanisms.

2.3

|

Invertebrate in vivo models

Invertebrate models such as Caenorhabditis elegans80,81 and
Drosophila melanogaster are popular in a variety of research
areas for their ability to provide relatively high-throughput,
but in vivo platforms. The conservation of many human genes
and signaling networks, combined with the small size and
relatively short lifespans of these models, facilitates the costeffective evaluation of a variety of phenotypes (eg, reproduction, locomotion, cognition) in a large number of individuals
(Table 4).80 This provides the ability to study phenotypes that
are challenging to assess in most vertebrate animal models,
such as healthspan (the part of an organism’s lifespan during which it is healthy).82,83 Invertebrate models can also be
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used in more focused interventional and mechanistic studies
that explore specific aspects of an established phenotype.84-86
For example, tea polyphenols were reported to modulate both
stress responses and fertility in D. melanogaster strains87 via
a non-target-ligand mechanism of action (Table 2), by modulating iron homeostasis. Recent advances in omics technology and the use of outbred populations further expand
opportunities for using D. melanogaster as a model system
for NP preclinical studies.

2.4

|

In silico models

When information on NP kinetics, dynamics, bioavailability,
clearance, and pharmacologic activities is limited, one useful approach is to apply computational or in silico methods
to leverage information from products with known chemistry, mechanisms of action, and activities. Data from more
highly characterized products can be integrated into dynamic
models, and in vitro to in vivo extrapolation (IVIVE) can be
used to predict biological responses.88-92 These approaches,
as outlined by the Tox21 Federal collaboration and the U.S.
Environmental Protection Agency’s ToxCast program,93-96
can be used to focus high-throughput in vitro and in vivo testing on compounds and concentrations that are more likely
to be biologically active and appropriate for each model.97,98
Such integrated approaches could be further developed to
probabilistically model the pharmacological and toxicological kinetics and dynamics of complex NPs.99
Speakers described several critical, often broadly applicable considerations for utilizing in silico models. First, the
purpose of the model must be clearly defined, and the model
appropriate and sufficient to fulfill the purpose. Second, as
for any research, if experiments that provide the input data
are not appropriately designed in the beginning, no amount
of computational modeling will yield translatable information. Third, variability and uncertainty in the data that inform the model, as well as correlations between parameters
must be considered. Uncertainty and variability in model
outcomes are acceptable but must be quantified, and in optimized models they should be similar to real-world variability. Preliminary models may be continuously refined, using a
“learn and confirm” strategy, or as understanding, for example, of NP pharmacology increases. Fourth, end users must
understand the computational (or any other) model’s limitations, the extent to which it is similar or dissimilar to the biological system of interest, and how the outputs compare with
population-derived data, other real-world data, or with data
from other models. Finally, computational models and the
data used in their development must be made findable, freely
accessible, interoperable and reusable (FAIR),100 just as information for in vitro and preclinical in vivo models must be
findable and sufficiently transparent to support replication.

2.5

|
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Ethnobotanical approaches

Another typical starting point for translational research is
traditional NP use, particularly the use of plants in traditional
medical systems. When basing NP research on traditional
use, it is essential to consider and thoroughly document how
the NP is sourced, identified, prepared, and used in the traditional contexts (Table 3). Intra-species variation and growing conditions strongly influence the metabolic profile of
a plant and differences in harvest and preparation will also
alter critical product characteristics.101,102 Many different
uses may be described for a given species, and traditional
healers have frequently been reported to use only specific
subtypes of a given species. Awareness of such practices
has the potential to be highly informative for the identification of bioactive components.103 Analogous considerations
apply to fungal and animal sources of NP. Good practices
for reporting botanical NP sourcing, identification, characterization, vouchering and archiving have been previously
described elsewhere.12,18,19,104-106 Comprehensiveness and
transparency in reports of biomedical research on traditionally used plants have increased in recent years.107 There
TABLE 3

Highlights of good practices for NP integrity including
standardization, formulation, characterization, and quality control
1. Quality control. Identity and purity of all materials used,
regardless of the supplier, should be verified (independent of
supplier) prior to use. Appropriate storage and handling conditions should be maintained and monitored by stability testing
at least throughout the duration of the study (consult, eg, the
NCCIH Natural Product Integrity Policy18 and the NSF Stability
Testing Guidelines for Dietary Supplements). To the extent
feasible, comprehensive chemical analysis of product should
be performed; minor product components or impurities can be
responsible for or affect measured activities.
2. Product specifications:
a. Chemistry. Identification of product components required
for the bioactivities studied provides critical information for
studies of bioavailability, pharmacokinetics (PK), and pharmacodynamics (PD) and should enhance the replicability and
clinical relevance.
b. Formulation. Consider the effects of NP formulation and matrix (eg, capsule, liquid, food) on bio-accessibility, bioavailability, PK, PD, and activity. These may differ significantly
between an isolated NP constituent and the same compound in
the context of a complex food matrix.
c. Sensory characteristics. Sensory acceptability must be considered for all in vivo research, and effectiveness of masking of
placebos or active comparators must be considered in CT.
3. Translation from ethnomedicine. If basing an intervention on
ethnobotanical observations, consider replicating traditional
practice as closely as is feasible. For example, highly processed
extracts will likely have different activities than a multi-botanical decoction (see 2a and 2b). Contextual differences (environment, behavior, genetics) may also affect the outcomes.
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are cases, however, where the available records predate the
availability of geolocation data on growing sites, or where
the need to protect ecologically or culturally sensitive information may limit what can be published.108,109 Where a
similar use or outcome is reported for the same or closely
related species across cultures and geographical regions,
those similarities may provide priority clues for translational research.
Translation from traditional to modern practice may be
limited by important differences110 (Table 3). Traditional practices commonly combine multiple NP sources (eg, multi-botanical) into one intervention and are often associated with
specific concurrent behaviors (eg, rituals, behavior changes,
possibly including dietary changes). Moreover, if documented
traditional practices and the NP outcomes to be studied differ
substantially, it may be inappropriate to claim the traditional
or typical use as supporting data; the differences between
modern medical diagnoses and practices and traditional principles of diagnosis and practice may be too divergent to base
claims for modern application on traditional use. Moreover,
where a planned NPCT is expected to use a highly processed
(single) botanical, information from traditional use may also
lack relevance, as the bioactivity and/or the absorption, distribution, metabolism, and excretion (ADME) properties of the
highly processed product may differ substantially from those
of a (multi-component) traditional preparation. Where the NP
and the study population are close to historical use and users,
traditional practice may provide initial parameters for dose
range to be used in research. In instances where no clear typical usage exists, for example with green tea extract capsules,
speakers recommended that preclinical studies prioritize the
determination of a therapeutic window and administer the
lowest dose to achieve concentrations required for the biological and/or health effect of interest.9

3 | N P CH A R AC T E R IST IC S
CR ITICA L FO R R E P L ICA B IL IT Y
3.1

|

NP specifications and integrity

The ultimate biological effect of an ingested, complex NP
results from a dynamic interplay of factors: NP chemical
composition, physical characteristics,111,112 bioaccessibility,
bioavailability, metabolism, and target population characteristics including sex, age, genetics, background diet, and
other environmental exposures.113 This subsection begins by
summarizing issues inherent to the integrity of the NP intervention and subsequently addresses target-related sources of
variability.
Replicability of outcomes depends on correct and
clearly reported identification and archiving of source

materials12-14,17 and consistent preparation and activity of
the NP.17,22,26,114 Some attendees felt that since the effects
of complex NP preparations may not be due to only the
identifiable components, transparent reporting of methods,
including consistent product preparation and quality control via an in vitro assay relevant to bioactivity, is sufficient
for replicable NP research. Others argued that in many research context it is also critical to understand which NP
components are responsible for the bioactivities of interest, as this information can inform NP quality control, as
well as being utilized in assessments of bioavailability,
pharmacokinetics and to inform comparisons of different
studies115 (Table 4).
Minor product components, impurities, instability, and
chemical changes due to instability, resulting in the occurrence of degradation products can be responsible for
some or even all measured activity. Instability has been
demonstrated for a variety of prominent bioactive botanical
marker compounds. These include ligustilide (a constituent
of dong quai), which is very unstable and prone to redox reactions and photo-induced dimerization;43,116,117 desmethylxanthohumol, a chalcone found in Humulus lupulus, or
hops, that forms the phytoestrogen, 8-prenylnaringenin,
via Michael addition;118 and curcumin, found in turmeric,
which is known to form a myriad of degradation products
and metabolites.44 These chemical changes can modify bioactivity through a variety of mechanisms97,119,120 and represent factors that appear to be minor (Residual Complexity,
see go.uic.edu/residualcomplexity), but may significantly
alter biological activities and therefore require monitoring.
A number of organizations have published general guidelines for stability testing, which are relevant for dietary
supplements and other NPs, including the NCCIH Policy
on Natural Product Integrity18 and guidelines published
by the International Council for Harmonisation (ICH; ich.
org).
Variations in growing conditions generate variations in
relative levels of NP constituents; differences in constituent levels are also seen between closely related species
interchangeably used in similar contexts NP.121 For example, the licorice source plants, Glycyrrhiza glabra L. and
G. uralensis Fisch. ex DC differ significantly in the ratio
of liquiritigenin to isoliquiritigenin, as well as in congeneric constituents, and are therefore expected to have different bioactivities.122,123 Characterization sufficient for the
detection of such minor components, known or unknown,
is therefore critical for quality control and for monitoring
batch-to-batch variation and stability.15,124 Identity and purity of all materials used, regardless of the supplier, should
be verified prior to use.14,124 Descriptions of approaches
to NP selection and characterization have been published
recently.17,22,114,125
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Chemical and metabolic factors

ADME is a multistep, dynamic biological process that may
be modified by product characteristics as well as by host
characteristics115,126-129 including physiology and behavior.
NP processing methods and final formulation can alter the
chemical profile, stability, bioaccessibility, bioavailability,
and metabolism of a NP.111,130 For example, soy germ isoflavone glucosides incorporated into pasta can be hydrolyzed to
aglycones by wheat β-glucosidase.131
In contrast to most preclinical models, humans are generally diverse in genotypes, diets, other behaviors, and environmental exposures. Moreover, host genetics and cultural
milieu profoundly affect flavor perception.132 If the NP will
be delivered in or as part of a food, liquid, capsule, or tablet,
acceptability of flavor, texture, and or tablet size are essential.
For both CT and generally available commercial products,
consumer burden is another critical factor; this may include
the number of capsules required, ease of swallowing capsules
or tablets, cost, and portability. Thus, sensory testing and burden, as well as stability of the NP preparation are critical for
successful translation of an intervention (Table 3).
Human microbiota are generally much more varied than
those of lab animal models, reflective of both genetic diversity133 and differences in past exposures.134 Run-in periods
prior to pharmacokinetic and metabolic assessments can
increase the relevance of preclinical animal models to longterm dietary patterns and provide important information for
comparison with post-intervention metabolite profiles. A
critical consideration is that, even where preclinical in vivo
studies are designed to better model (CTs), the models usually differ from humans in their greater uniformity of background diet, control of prior exposures to the relevant NP,
dietary requirements, and metabolic capacities (Table 4). For
example, taurine is an essential nutrient for cats,135 but synthesized by humans and rodents, while ascorbic acid is essential for humans, but synthesized by most other animals.136
Human genetic differences and variations in gut microbiota cannot be considered to be independent, as both direct
and indirect effects of host genetics on gastrointestinal ecology have been reported.133,134,137,138 Both background diet
and bioactive NPs affect host physiology directly, as well as
through modulation of the microbiota, and the microbiota in
turn contribute to modulation of NP processing.139,140 Nonabsorbed polymeric polyphenols may, for example, modulate
absorption of polyphenol monomers in humans, such that
history of exposure significantly influences pharmacokinetics.141 Effects on the host may, in turn, modulate microbial
ecology and metabolism, while changes in microbial populations or gene expression may modulate host physiology,
including ADME, collectively resulting in dynamic host-microbiota interactions that modulate or even generate the observed responses to ingested interventions.141-146
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Gastrointestinal microbiota have been shown in many
cases to be required for the generation of bioactive metabolites of NPs. For example, gut microbiota can convert grape
constituents to phenolic acids such as 3-hydroxy benzoic acid
and dihydrocaffeic acid, which have been reported to inhibit
β-amyloid and α-synuclein oligomerization, respectively,
and epigenetically modulate gene expression.3,147 Speakers
stressed the importance of a strong, though not necessarily
complete, understanding of the pharmacokinetics and metabolism of a NP intervention for optimizing the design of
large-scale CT, although opinions differed on whether such
knowledge was necessary before pursuing early-phase trials.
Presenters highlighted cases where the biological activities of enantiomeric NPs differ significantly. For example,
a cancer preventive effect of soy in rodents could be replicated using the R-(+) enantiomer of the isoflavone metabolite equol, but not the S-(-)isomer produced in vivo by the gut
microbiota.148-152 The microorganisms responsible for this
conversion are widely present in rodents, but only found in
only 20%-30% of adult humans, a difference that may contribute to discrepancies between observations in rodents and
humans. This finding emphasizes the importance of considering, characterizing, and fully reporting the chirality of NPs
and their metabolites, as well as of understanding the role of
the gut microbiota. It was pointed out that translational relevance of in vitro HTS assays might be substantially improved
through the integrated use of replicable model systems able
to mimic the generation of translationally relevant metabolites by the target animal or its gut microbiota.

4 | TRANSLATIONAL
RELEVANCE OF PRECLINICAL N P
RESEARCH
4.1

|

General considerations

Preclinical in vivo models are widely used in biomedical
research, and are often considered a prerequisite for CT.
These models provide critical information on the biological
response to a product that in silico and in vitro models cannot currently provide in a reliable fashion, including on bioavailability, metabolic activation and deactivation, PD, and
toxicology. In vivo testing also provides a basis for choosing
dose ranges to be tested in CT.
In selecting any in vivo preclinical model system, investigators must keep in mind ways in which the differences between the model and the clinical application of interest are
likely to affect inference from the study.20 The model selected
should be appropriate for the experimental question based on
the organism characteristics considered most critical to the
target biology. The likelihood of translational relevance of a
preclinical model to a clinical or other experimental question
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can be considered in terms of different types of model validity, including face validity (similar phenotype, lower probability of successful translation), construct validity (similar
mechanism and phenotype, better probability of successful
translation), and clinical validity (demonstrated clinical predictive success)153-156 (Table 4). For example, short-lived
invertebrate models may be particularly advantageous to
understand NP effects on healthspan, as these species conserve the target-of-rapamycin, insulin/IGF-1-like signaling,
and sirtuin pathways, which have been shown to modulate
healthspan in organisms ranging from yeast through C. elegans and D. melanogaster to mammals.82
Many factors that differ between preclinical in vivo models and people may influence the biological effects of a NP.
Background diet and dietary history can influence NP absorption and metabolism. For example, the absorption and
PK of flavan-3-ols are altered by exposure history, as well as
by host factors such as obesity and diabetes.112,141,157,158 This
demonstrates the critical importance in research on humans
of considering, assessing, and reporting background diet and
history, as well as standard biometric parameters. Assessing
correlations among human genomic, transcriptomic, proteomic, or metabolomic data, and between these and outcomes following a standardized exposure may elucidate
mechanisms that underlie differences in the absorption or
generation of, or exposure to, bioactive constituents or bioactive metabolites,128 and allow prediction of responders versus
non-responders. These approaches can enhance translation
between epidemiological, preclinical, and clinical studies.

4.2

|

Selection of a mouse model

Mice are frequently the model species of choice for in vivo
preclinical research, due to their relatively small size and
short lifespans, and the large number of strains and large
body of literature available. Nevertheless, mouse and other
in vivo preclinical models differ from humans in many
known and unknown details, both intrinsic (eg, genetic,
immune,159-164 surface area: volume ratio, lifespan165) and
extrinsic (eg, captivity, diet, history), which, depending on
the research question, may substantially affect translational
relevance.166
It is critical to remember that each distinct inbred strain
may respond differently to an intervention126,167 that the
same strain supplied by a different vendor (or with different
gut microbiota) may respond differently,168 and that sex differences in response may appear only in specific species or
strains.169-172
A wide variety of approaches are used to increase the predictive validity of mouse models. Transgenic mice are commonly employed to enhance construct validity; guidelines for
rigor and transparency in research using mouse mutants have

TABLE 4

research on NP

Highlights of good practices for preclinical in vivo

1. Product translational relevance and replicability:
a. Equivalent product formulation. NPs used in preclinical
studies should use similar or analogous formulation(s) to the
intended human studies.
b. Biotransformation. Track the actual bioactive compounds,
which may be generated from precursors in the NP by the host
or the host’s gut microbiota. Either or both may transform NP
constituents to active or inactive compounds. These transformations may differ between models and humans, and among
humans, and affect replicability of results.
c. Dose-ranging. Doses used in models should be comparable to
anticipated human dosage. Initial dose ranges may be based
on traditional use or MPS dose-response studies, derived
using PBPK modeling, or from preclinical in vivo studies
using appropriate scaling approaches. A clinical study is still
required to establish dose-response, assess safety, and determine PK and PD in the target population.
2. Model translational relevance:
a. Model selection. Consider the translational relevance for the
specific research question of different species and strains,
humanized, outbred, wildling, and/or genetically modified
models. Heterogeneity in the model organisms may contribute
to the ability to predict responders vs non-responders.
b. Documentation. Document as much as possible. Endogenous
(eg, age, sex, physiological/health status, genetic), and external
factors (eg, environment, including background diet, exposure history, enclosure size and enrichment, circadian timing,
season, duration and timing of exposure relative to outcome
assessment, handlers and handling methods) may affect outcomes. Make these records findable, accessible, interoperable,
reusable (FAIR).100
3. Validated methods for de-risking the NPCT (see also Figure 1):
Develop and use validated assays to assess achievement of go/no-go
criteria based on as many components of the mechanistic model as
possible (see Figure 1), for example, achievement of effective concentrations of the bioactive component(s) at in vivo targets, target
occupancy, and modulation of relevant biological networks.
4. Specimen collection, analysis, and archiving. Collect and appropriately document and store specimens needed for assays
described in point 3, and as applicable, fecal, or other relevant
samples to facilitate assessment of any association of the gut
microbiota with differential responses. In analyses, include
approaches to control for known artefacts, such as reagent
contamination that can strongly affect outcomes in low biomass
microbiome specimens.195

been published.173 Transgenic constructs allow experimentation on specific human pathways and targets of interest. Where
the genetic mechanism of interest is unknown, for example in
toxicity testing166,174 or research on neuropathic pain,175 the
genetic heterogeneity of outbred mice174 may provide important information that is unavailable from inbred strains
without otherwise affecting outcome variability.176 Many different approaches to “humanizing” mice have been utilized to
enhance predictive validity for specific research disciplines
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or questions. Employing the severe combined immune deficiency mouse (SCID) is one such approach, whereby human
peripheral blood cells, and cells of other human fetal immunological tissues such as bone marrow, thymus, or liver are
introduced (usually an NOD-SCID-γ mouse).177 Another
approach involves developing transgenic and chimeric mice
in which specific human genes are expressed. Various approaches have also been utilized to generate mice with “humanized” gut microbiota, which have been found to have
significant clinical predictive validity in developing anti-infective, autoimmune disease, cancer, and transplant therapeutics.178-180 Inbred mice reconstituted with microbiota from
wild mice have also been reported to have increased translational value.181,182 In their natural environment mice, like
humans, are exposed to microbes, including pathogens, and
thus should be regarded as metaorganisms, with their own
specific microbiota (including bacteria, fungi, and viruses).
Returning natural microbiota to standard laboratory mice was
found to significantly improve the model’s ability to predict
human immune responses in two preclinical studies.183

4.3 | Model- and context-related
considerations
Optimization of preclinical research for relevance to future
NPCTs as well as general human use requires not only careful
consideration of the choice of models but also of intervention
dose,184 composition, and delivery (Table 4). As discussed
above, when research and intervention are founded on a traditional use, available ethnobotanical and ethnopharmacological information may be used for guidance (Table 3). Clinical
and preclinical interventions should be as similar or, where
more appropriate, as equivalent as is feasible, bearing in mind
species differences,185 as well as any age-, sex-, size-, or
health status-related differences which may affect behavior,
absorption, metabolism, and/or toxicity. Allometric or mechanistic modeling approaches can be used to scale to human
dosing from preclinical in vivo data, and vice versa.151,184,186
Background diet, as well as other environmental exposures, including medications, alcohol, smoking, and air
quality may also have important effects on NP bioavailability, metabolism, and biological effects in both humans and
animal models. In the context of NP-diet interactions, it is
critical to consider species-specific dietary requirements
and optimal diets (eg, differences in ascorbic acid requirements,187 optimal amino acid or lipid compositions),185 as
well as species differences in biosynthetic abilities188 and
digestive anatomies.189 When comparing results across studies, it should be noted that differences in local regulation of
vertebrate animal research (eg, the European Union prohibition on feeding animal-derived ingredients to herbivores)
result in substantial differences in commonly used basal diets
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or chows. Researchers must carefully consider, for a given
research question, whether background diets should be the
same for different species, or at similar levels of optimization
for each, or whether both possibilities need to be included
as controls. As discussed below, physiologically based pharmacokinetic (PBPK) models may be helpful in making dose
adjustments for different subpopulations.
Diet and circadian rhythm interact in their effects on health,
gut microbiota, and metabolism.190,191 These effects are modulated by sex in organisms ranging from fish and mice through
humans.192-194 Through their effects on gut microbiota, NPs
may have important effects on their own metabolism and on
the generation of active metabolites which, in turn, may significantly affect both PK and PD. In addition, changes in the
gut microbiota may exert separate direct or indirect effects on
animal biology and health.168 Good practices for characterization of the gut microbiota have been discussed elsewhere.195
Preclinical in vivo models are often used in environments
that are optimized for the investigators and different from the
species’ natural habitat. This context by itself is likely to affect experimental outcomes and may also modulate the effects
of an experimental intervention. In either case, the experimental environment is likely to affect translational relevance.
Investigators need to acknowledge these often unavoidable
factors and consider them when inferring the translational
relevance of studies.156 In general, given the range of interrelated factors that may modulate the effects of a dietary intervention, it is critical that supporting data include experiments
rigorously designed to falsify the hypotheses tested, for example, to test whether the proposed bioactive constituents or
metabolite and/or proximate targets are indispensable and
inducing for the effect studied (Figure 1).35,196
The robustness of a result is optimally assessed by attempting to replicate the study not only in the same model,
by those originally reporting the result and others, but also
across models based on a range of species, genotypes, and
phenotypes. Recording as much information as possible
about the model and the environmental conditions under
which it was used may help others to replicate the studies
or facilitate exploring why a finding failed to replicate, or to
translate to another model or species.

4.4 | Genetic diversity and gene-NP
interactions
One critical difference between most preclinical in vivo models and humans is that the former are usually inbred, except
as discussed above. Where the bioactive compounds are
known, and population differences in health response have
been reported, interrogating those differences may lead to
the elucidation of underlying gene-environment interactions.
For example, common genetic variants in two fatty acid
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desaturase genes (FADS1 and FADS2) appear to modulate
the response to dietary polyunsaturated fatty acids (PUFA),
resulting in differences in resulting levels of pro- and antiinflammatory lipid mediators and differences in risk for
inflammation-associated health outcomes such as asthma,
rheumatoid arthritis, and cancer.197 Tracking the effects of
prevalence of these variants might shed light on inter-trial differences in NPCT outcomes with PUFA interventions.197,198
Similarly, a variety of factors including biometrics and genetic polymorphisms appear to be responsible for observed
differences between black and white American women in associations between serum 25-hydroxy vitamin D levels and
bone fractures.197-199

4.5

|

In silico modeling approaches

Quantitative or computational modeling and simulation are
beginning to show their utility in optimizing NPCT design.
Quantitative systems pharmacology (QSP) encompasses
computational methods including statistics, pharmacometrics, PK and PD modeling, mechanistic or PBPK models, in
vitro-in vivo extrapolation, and machine learning approaches.
QSP is often employed in drug development to integrate data,
optimize experimental dosing regimens, identify sources
of inter- and intra-individual variability, predict efficacy
or toxicity, or estimate appropriate doses for different subpopulations.200-202 PBPK models incorporate physicochemical data (eg, molecular weight, pKa, lipophilicity), in vitro
or preclinical data (eg, on metabolism and transport), and
population-specific data (eg, organ volumes, tissue composition, blood flow) to model ADME. PBPK can be used to predict equivalent exposures for humans and other species, for
both translational and reverse-translational studies (Table 4).
Sensitivity analyses can allow comparison of the magnitudes
of the effects of different parameters on the outcomes. These
models may also provide insight into the interplay between
metabolizing enzymes and transporters, inter-individual variability due to intrinsic (eg, pharmacogenomics, age, sex) and
extrinsic differences (eg, drug, food, or other environmental exposures). Perhaps most importantly, these computational models can highlight the most significant gaps in the
data,203-205 as well as support evidence-based selection of initial dose ranges for CT.
The application of quantitative pharmacology to complex
NPs is in its infancy. In addition to the inherent chemical complexity of NPs, understanding of the pharmacology and metabolism of the individual chemical components is mostly very
limited. Nevertheless, application to NPs of modeling and simulation approaches that incorporate uncertainty and variability
can provide estimates of differences among populations, inform dose selection and go/no-go decisions, and provide early
estimates of the probability of rejection of the null hypothesis.

5 | GOOD PRACTICES FOR
M OVING TO A NPCT
As outlined above in the section “NP Characteristics
Critical for Replicability,” speakers emphasized the importance of having rigorous and replicable data on the
chemical components of the NPs required for the biological activities of interest, as well as evidence for the activity of interest itself from at least two distinct in vivo
preclinical models. This information is critical for both
NPCT planning and for post-trial interpretation of results
(Figures 1 and 2).

5.1

|

NPCT planning

The foundational information should rigorously support
a clear and specific definition of the question to be addressed by the NPCT, framed in quantitative terms, and
matched to the study population, the evaluation period,
and the primary and secondary outcomes.206,207 When
strong evidence supports the requirement for specific bioactive components and specific in vivo targets, this information can be used to develop approaches for de-risking
a project, that is, assessing whether the accumulating data
are consistent with the hypotheses and support continuation. This information enriches the ability to design a
NPCT that will allow evidence-based interpretation and
planning of next steps regardless of the completed outcome, as shown schematically in Figure 1, by providing
the ability to:
• define minimal effective concentrations in plasma or at the
targets;
• develop methods to assess in vivo engagement of putative
targets, especially methods which may be translationally
relevant, such as non-invasive methods;
• use those methods to assess the relationship between target
engagement and outcomes;
• elucidate causal cellular or molecular mechanisms mediating the generation of the biological or behavioral responses
of interest (ie, PD biomarkers).
This mechanistic information will be critical for clinical
dose-ranging and dose optimization studies, as well as for
detecting potential “drop-ins”: given the broad availability of many NPs, placebo group participants sometimes
present with anomalously high levels of apparent offprotocol exposure to the intervention. Off-protocol exposures, whether accidental or intentional, may hamper the
ability to interpret the results. Knowing which compounds
are indispensable and inducing for the bioactivities of
interest also allows investigators to ensure that sufficient
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F I G U R E 2 Good practices for actionable results in future translation of Natural Products research to Clinical Trials (NP2CT). Translation
is most informative and cost-effective when CT Phase (I vs II) and design (eg, RCT, adaptive) decisions are built on a solid and rigorous evidence
base (pyramid and tabletop). The choice to proceed to an NPCT and the determination of the most appropriate trial type (examples on sphere)
depends on the extent and strength of supporting data available (table legs and segments). If multiple supporting data elements are missing or weak,
an earlier phase CT may be more informative and cost-effective than a Phase III CT. If a substantial number of CT design choices or parameters
lack supporting evidence, a more useful next step may be research addressing those gaps via either preclinical research or a mechanistic or early
phase NPCT

time is allowed for washout between inventions in crossover designs.26 Equally important, knowledge, for example, of minimal effective concentrations and targets, or
of metabolites indispensable for activity or genotypes
required to generate those metabolites, can be used to
generate minimal go/no-go criteria, which help identify
CTs that are less likely to be informative, and ensure that
only treatments with strong supporting evidence move forward to larger, confirmatory CT (Figure 2). Elucidation
of such causal, molecular mechanisms of action may
also be useful to predict which participants are likely to
respond well or poorly to a specific intervention. Similarly,
understanding the molecular mechanisms between an initial target and the final, assessed outcome should enable
not only enhanced post-trial assessment of the validity of
the pre-trial mechanistic hypotheses but also contribute
to the ability to better predict individual responses to the
intervention.

5.2

|

Safety and dose selection

Safety issues that arise in preclinical testing must be carefully considered prior to CT, and safety outcomes must be
included in all NPCTs.208 Safety in the context of a NPCT
cannot be inferred from traditional nor contemporary use if
the product, dose, route, schedule, and context of use differ
(Table 3). Dosing in larger NPCT should be based on doseresponse data from Phase I/II studies with safety data. Doseranging in Phase I NPCT may use allometric or mechanistic
models to build from in vivo preclinical studies (Table 4), as
described above, or, where appropriate, may be based on current clinical practice or traditional use.
As described above and summarized schematically in Figure
2, a variety of rigorous foundational information provides critical input for translation to later-phase efficacy CT, with much of
this information requiring input from other types of NIH-defined
CT. This foundational information includes the following:

54

|   

SORKIN et al.

• safety of the product to be used in the NPCT, in the population to be studied;
• product specifications (for interventions and any controls),
including chemistry, stability, consumer acceptability (including sensory qualities), and packaging;
• bioavailability, PK, PD of the product to be used in the
population to be studied;
• dose-response properties.

5.3

|

Post-trial interpretation of results

In the absence of the foundational information described
above, and without meeting the resulting go/no-go criteria,
it will be more challenging to interpret a failure to reject the
null hypothesis, as lack of effect could be due to many factors
(Figure 1). These include, but are not limited to an incorrect
hypothesis regarding the relationship between target engagement and outcome, or less interestingly, failure to achieve
sufficient levels of bioactive compounds or target engagement. As the following variables could have an important
influence on the results, obtaining information on these for
each participant can also be critical to the interpretation of
NPCT outcomes:
• Background diet—habitual and during the NPCT (the latter is potentially controllable).
• Age, sex, race/ethnicity, body size and composition, health
status (especially with respect to outcomes of interest),
co-medications, smoking, geography.
• Genetic and epigenetic data, including characterization of
microbiota structure and gene expression, especially as
they relate to ADME of the NP.134,168,195,209 When known,
relevant genetic variants exist, for example, in metabolism,
specimens for genetic analyses should at least be collected
and saved.
• Sensory characteristics (texture, flavor, odor; pill, capsule,
etc., number and characteristics) of products to be used in a
NPCT must be acceptable to trial participants, who should
not be able to distinguish amongst intervention(s) and controls. Information on participants’ pre-trial beliefs about
product efficacy, and post-trial conclusions with respect to
the intervention they received should be collected as this
may critically inform interpretation (Tables 3 and 5).

5.4

|

Addressing expectancy effects

Human responses in NPCTs are also influenced by expectations, often resulting in either placebo or nocebo effects. These
effects may vary substantially for different populations and
interventions (eg, color, size, number of capsules, estimated
cost).210 Through conscious and subconscious processes,

people (researchers as well as participants) can be biased when
assessing and reporting symptoms, functional abilities, and
other patient-oriented outcomes. Whenever feasible, blinding/
masking and other approaches should be employed to minimize
such biases, including in preclinical studies (Tables 1 and 5).
Conscious and subconscious mind-body processes can also
lead to real positive health outcomes, including in apparently
objective, quantitative outcomes such as blood pressure.211
Because blinded “placebo” comparison groups are likely to
achieve real health benefits through these processes, the magnitude of benefit estimated by comparing conventionally blinded
placebo and treatment (intervention) groups is likely to underestimate the amount of benefit that would be observed when
comparing non-blinded treatment to no treatment.212 Therefore,
when feasible, no treatment and open-label treatment comparison groups should be included in RCT design, so as to arrive
at best estimates of real-world effect sizes, as well as effect size
from conventional blinded comparison.

5.5

|

Sample and effect size

Sample size calculations must reflect simultaneous consideration of trial phase and design, estimated and targeted
magnitude of treatment effects, and statistical power.207
The targeted effect size should be biologically plausible,
and based on the degree of benefit that patients, consumers, or practitioners would consider sufficiently beneficial
to be worthwhile, given other considerations such as cost,
inconvenience, side effects, and potential for serious adverse
effects213 (Table 5). Effect sizes should not be based on estimates from the literature as a whole, which almost always
leads to biased estimates,214 inasmuch as the published literature contains a biased selection of all empirical research
that is performed. Meta-analytic evaluations of the literature
have consistently found that studies yielding null or mixed
results are substantially less likely to appear in the published
scientific record215,216 than those studies with strong statistical support for the tested hypothesis. This occurs even where
the amount of collected data renders these “negative” studies
highly informative. As a result, statistically significant published results often provide inflated effect size estimates.217
Increased use of registered reports, for example, as provided
by preclinicalresearch.eu, may begin to address this issue and
decrease the bias in the scientific literature.

5.6

|

Analysis of the literature

Beyond publication bias, two additional factors that challenge the translational relevance of the published literature
have been widely agreed upon: analytic flexibility during the data analysis218 and low statistical power.40,218,219
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TABLE 5
design

Highlights of major considerations for clinical trial

1. Statistical power. Base sample sizes on the smallest effect size of
interest, in the context of existing options and consumer burden.
Use best current meta-analytic approaches to assess bias in the
literature, and to correct for bias in reported effect sizes.214
2. Transparency and statistical analysis plans. Clearly describe and
document statistical analysis plans before beginning the trial.
3. Comparison groups and expectancy/placebo. Base controls and
interventions on the supporting data and the resulting hypotheses. The inclusion of no-treatment, and open-label treatment
groups, as well as conventional blinded comparison groups,
in RCTs provides best estimates of real-world effect sizes.
Development of inert but effectively masked placebos for NPs
with strong color or odor (eg, with similar or masking odor or
color) may be challenging. Assessing participant perceptions of
product efficacy pre-trial, and of intervention allocation posttrial may provide critical information for interpretation of trial
results.
4. Optimal clinical trial paradigm. Adaptive design (AD) NPCTs
may be a more efficient approach to optimizing, and testing the
efficacy of an intervention, if the evidence base for some CT parameters is lacking. AD CTs require statistical rigor to avoid bias
in the interpretation of the results. ADs may be a good choice for
Phase II trials.

All of these factors need to be taken into account when
building on published research. Nevertheless, it should
be kept in mind that a substantial portion of the scientific
literature does consist of reliable and replicable findings.
An important challenge for researchers navigating this intrinsically biased body of literature is to determine which
research is reliable enough to build on, and which research
is more likely to not be replicable.220 Because it is practically impossible to determine whether a finding will replicate based on a single study,221 meta-analytic techniques
have been developed to aggregate evidence across studies.
However, analytic flexibility and selection for significant
effects in small studies lead to upwardly biased effect size
estimates. Novel bias detection techniques can identify different types of biases: P-curve analysis222 can identify lines
of research that consist of false positives, and under some
circumstances PET-PEESE meta-regression222,223 can calculate bias-corrected effect size estimates.
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Clinical trial design

In the design of a later Phase NPCT, it is important to recognize that estimated treatment effects from pilot studies
are necessarily imprecise. Pilot studies may under- or overestimate the true effect size (but, as noted above, publication bias generally selects for overestimates). Effect size
estimates and sample size calculations should, therefore,
be conservative and based on prospective meta-analyses
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(https://methods.cochrane.org/pma/what-pma-0) or other
rigorous meta-analyses, that is, those which include all eligible studies designed and performed, or those which pass
rigorous bias detection tests, such as the p-curve analysis
described above, with PET-PEESE meta-regression used
in estimating effect sizes. Results of pre-registered, rigorously performed, and analyzed pilot studies may also be
used to estimate effect sizes when convergent, corroborating, or similar results are obtained in independent research
from separate groups, using approaches based on different assumptions (triangulation or orthogonal approaches),
such that any artefacts or sources of bias are likely to differ
for the different approaches.224,225 Adaptive designs (AD)
(see below) and sequential analyses (https://methods.cochr
ane.org/pma/what-pma-0) can be used to design informative studies when uncertainty about the effect size estimate remains. An argument can be made that later Phase
NPCT intended to test whether an intervention is beneficial
should be undertaken only where the estimated effect size
from rigorous methods such as those described above is at
least as large as the estimated smallest important difference
or smallest worthwhile effect213 for the intervention and
outcome to be tested. This would not apply if the hypothesis to be tested is that the intervention has no effect, for
example, on an adverse outcome.
Where the goal is to determine the maximum potential of
an intervention, Phase II studies should enroll those subpopulations predicted to have strong responses, a practice called study
“enrichment.” While enrichment, and the inclusion of multiple
endpoints are appropriate for Phase II NPCT, it is important to
recognize that these designs tend to bias the results of Phase
II studies toward the conclusion that moving forward is worthwhile, although positive findings could be due to chance.
Because NPCT are costly, time-consuming,226 and dependent on voluntary human participation,11 approaches that
can support making trial design and prioritization decisions
which optimize acquisition of replicable, actionable results
(Tables 5 and 6) are in high demand. Multilevel modeling can
be used in conjunction with existing data to identify parameters most strongly associated with the outcomes of interest.227
Simulation modeling can also be used to identify trials that
are unlikely to reject the null hypothesis.228
AD can provide an efficient yet rigorous approach to
honing the parameters of a NPCT while obtaining preliminary data on clinical effect of the intervention(s). An
AD uses accumulating information to implement changes
to the design during the course of the trial.22,229 Changes
in the trial must be based on pre-specified decision rules.
Changes made on an ad hoc basis may not preserve the type
I error rate (false positives), and may lead to bias in parameter estimates or other problems with statistical properties.
The many variations of AD include early-stage AD, which
may focus on dosing, exposure, heterogeneous responses,
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or biomarker responses. As it is assumed that AD are exploratory studies, there is less concern about the control of
type I error. AD methods are more accepted in the learning
(exploratory) stages of CT. Some key variations of AD include the following:
• Adaptive enrichment designs, which target therapies to
participant subgroups most likely to benefit. In such designs, a trial initially enrolls a broad population. The initial
study period (discovery phase) reveals participant groups
most likely to benefit from treatment. In the second phase
of the trial, only those subgroups most likely to benefit
from treatment are randomized, providing increased power
to detect an effect.
• Sample size re-estimation designs refer to AD that allow
for adjustment of sample size based on an interim review
of the data. Sample size re-estimation based on revised
estimates of treatment effects has been controversial for
the reasons cited above. However, internal pilot designs
that re-estimate only “nuisance” parameters, such as the
variance of control group event rate, are more generally
accepted.
• Platform trials are useful for studying multiple targeted
therapies in the context of a single outcome, with therapies allowed to enter or leave the platform on the basis of
pre-specified stopping boundaries.22 This approach could
be used to choose between several different products in a
NPCT, for example, different preparations of NP material
from the same source, such as whole dried plant, different
extracts, and/or material enriched for one or more putative
bioactives.230 Such studies could be done under a master
protocol,231 defined as a protocol encompassing multiple
substudies, which may have different objectives. A master protocol supports coordinated efforts to evaluate one or
more investigational interventions in one or more subpopulations within the overall trial structure.
Adaptive seamless designs combine objectives traditionally addressed in separate trials into a single CT. First-stage results
inform the second stage, but final analyses use data from both
stages. For example, the first stage may establish preferred
dosage, whereas the second stage can assess the efficacy of
that dose. To avoid bias in the interpretation of results, such
designs require clear, comprehensive, and pre-specified criteria
and raise tricky statistical issues, as data from both stages must
be combined in a way that preserves key statistical operating
characteristics.
In general, most AD require slightly larger sample sizes
than a corresponding, conventional Phase II CT, but provide
increased opportunity to detect an effect, and can also lead to
timelier identification of ineffective (or clearly more efficacious) interventions, improving efficiency by allowing early
discontinuation of trials for less effective or ineffective products.
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TABLE 6

Highlights of major issues to consider in clinical trial
decision-making
1. Trial focus. Is the proposed trial well-justified? Are the evidence
for and magnitude of the effect, the size of the relevant population, and the need for the knowledge to be generated commensurate with the anticipated cost of a CT?
2. Likelihood of actionable information. What CT paradigm or
other next step is most likely to provide actionable information?
a. Next step: Is the most informative next step likely to be a
pilot trial, a larger CT, clinical research other than an efficacy
study, or research other than a CT?
b. NPCT protocol: Have trial/protocol design decisions been
sufficiently de-risked? Is there sufficient understanding of
the path(s) from initial target(s) engagement to outcome, and
availability of non-invasive assessments of these, to support
evidence-based decisions regarding the next test of activity whether or not the null hypothesis is rejected upon trial
completion?
c. Bioavailability: Are assays of bioavailability at the immediate
in vivo target available and translationally relevant?
d. Open ends: Can any remaining questions be sufficiently addressed via use of a rigorous, adaptive trial design?
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Value of information

Whether and how to pursue a NPCT depends on the value
of the information that the CT can be expected to generate.
Given the high costs of conducting a CT, it is of critical importance to prioritize the questions to be addressed.11 Value
of Information (VOI) analysis provides a framework for generating quantitative estimates of the value of further research
in a particular area. VOI estimates can serve as a guide for
prioritizing research resources.232
The basic framework for estimating the VOI is the product of several factors: (a) the value of the information to be
gained for individuals who would be affected by the findings, including both changes in health status and changes
in costs, (b) the number of affected individuals in the population, (c) the extent to which the information generated
would be adopted or implemented, and (d) the degree to
which the value of the knowledge gained will depreciate
over time as additional knowledge becomes available. This
estimated quantity is typically summed over the relevant
time horizon, adjusted by an appropriate discount factor
reflecting the preference for current over future improvements in health.
Generating estimated values for the elements of the
VOI calculation can itself be a costly and complex process. Depending on the NPs under consideration and the
effects to be tested, different levels of VOI analysis may
be undertaken. An initial level of conceptual VOI can assess whether any of the factors in the product are close
enough to zero that the overall VOI would be very small,
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indicating that substantial research investments would
not be justified. Depending on other characteristics of
the product under investigation, the health outcomes involved, and the specific data collection challenges to be
addressed, progressively more detailed approaches to VOI
exist, termed minimal modeling, full modeling, and maximal modeling, that provide more thorough estimates of
the value of the information to be gained from pursuing
additional research.232,233
The use of VOI analysis to support decisions regarding
which NPCT to pursue (Table 6) depends significantly on
the available research foundation. Assessing the VOI to be
gained to a representative affected individual requires definition of the outcome(s), and understanding of the effect
sizes to be achieved. Defining and estimating the size of
the relevant affected population requires understanding of
the dietary, environmental, and genetic context of the effects. Use of VOI in priority setting is still relatively new
and will benefit from further exploration and input from
researchers and decision-makers. In particular, VOI should
be assessed to understand the extent to which it changes
decision-making relative to conventional approaches, and
the health impact and monetary value that result from such
changes.
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The multi-disciplinary approach

Rigorous, evidence-based decision-making with respect
to the design and prioritization NPCTs ultimately requires
bringing together myriad research sub-disciplines. These
disciplines span from ethnobotany through NP chemistry,
food science, a range of modeling approaches, biomedical
specialties including CT design and statistics, to value of
information research. Notably, researchers who specialize in one sub-discipline often do not have ready access to
collaborators from other fields, or are unaware of relevant
state-of-the-art approaches from these areas. However, the
likelihood that an NPCT will be optimally informative depends not only on the rigor of the information contributed
by each sub-discipline but also the rigor with which the
different threads are brought together, achieving collaborative synergy. Deploying and synergizing the good practices
discussed by attendees at the September 2018 workshop,
across the full range of this disciplinary continuum and
from the earliest phases of developing data that may inform
a future NPCT, should help focus translational NP research
on objectives that are most likely to contribute to the design
of, and increase the knowledge gained from future NPCTs
(Figure 2).
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Controversies

Two major areas of controversy at the workshop related to
translation from traditional health practices. The first of these
areas of disagreement was the appropriateness of the RCT
approach for the study of traditional practices, with several
attendees arguing that RCT methodology is not well suited to
studying them. Most attendees, however, supported the need
for NPCTs to assess the safety and efficacy of tradition-based
approaches in a 21st-century context, with the many associated differences, including in the interventions, and in individuals’ histories, environments, and behaviors. A second
area of disagreement was the extent to which it is necessary to
elucidate causal, molecular mechanisms of action, including
determination of bioactive substituents and their in-animal
targets, to support the design of an optimally informative
NPCT. A case was made that, in some contexts, adherence to
current good manufacturing practices, including rigorous adherence to standardized growing and processing procedures,
and in conjunction with an appropriate assay of systemic exposure, and, in some cases, bioactivity, is sufficient to ensure
NP replicability. However, many attendees felt that product
specifications, PK assessments, eligibility criteria, and outcome assessments should, to the extent feasible, be based
on strong mechanism of action evidence, preferably derived
from conceptually independent (orthogonal or triangulated)
scientific approaches. Attendees considered such evidence
to be critical both for optimal trial design and for the ability to interpret results after trial completion. Information
on the mechanism of action, including compound(s) indispensable for inducing effects, as well as biological target(s)
and response(s) indispensable for outcomes, may critically
inform the design and/or interpretation of an NPCT, from
product quality control through understanding the bases for
individual differences in response, and may support the ability to develop biomarkers of proximate effects, or biomarkers
useful to distinguish likely responders and non-responders.
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NCPT good practices

In preclinical research aimed at informing the understanding
of purported, causal, molecular mechanisms of action, good
practices include the use of biologically relevant concentrations of biologically relevant compounds and/or their in vivo
metabolites, in one or more relevant models. Participants
also emphasized the importance of including appropriate
controls for common artefacts encountered in in vitro assays for the activities of phytochemicals. Further approaches
that were highlighted as good practices for strengthening the
foundational data for NPCTs included: (a) high-throughput,
non-targeted approaches that can generate strong, specific
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hypotheses regarding molecular mechanisms of action of
chemically complex NP, (b) pre-registration of experiments
at the hypothesis-testing stage, rigorous adherence to experimental protocols, randomization, and masking, which collectively minimize the risk that unconscious biases influence the
results, (c) thoughtful consideration, when selecting model
systems, of translational relevance and clinical validity for
a specific research question, and (d) comprehensive and
transparent reporting, combined with meaningful and FAIR
data sharing. Participants discussed these issues for models
ranging from in silico through the burgeoning variety of cellbased models, from organoids through MPS, through in vivo
models from invertebrates to transgenic, outbred, wildling,
and humanized mouse strains.
Good practices for NPCT decision-making based on the
available foundational data were extensively discussed and
gave rise to the third major area of controversy at the workshop. Some attendees felt that n-of-1 trials234 based on traditional use and/or current practitioner experience provide
sufficient evidence for safety and efficacy, and are better
suited to tests of these approaches than RCTs. Others felt that
RCTs are critical, but that NPCTs should be undertaken only
when there is a strong likelihood that the outcome will influence practice. The foundation for such an assessment would
come from public health needs and a rigorous, evidence-based
effect size estimate, that predicts an effect magnitude considered worthwhile by practitioners and consumers, collectively
supported by multiple, distinct lines of evidence.225 The evidence base for such assessments is strongest when it includes
experiments designed to falsify the hypotheses tested, such as
chemical, genetic, or other knockdown studies.11,35
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Outlook

While many of the practices discussed at the workshop are
already employed by numerous NP researchers, few, if any
reported NPCTs have combined the full breadth of state-ofthe-art approaches when investigating the effect of a NP on
a specific health outcome. Integrating these practices in the
development, implementation, and interpretation of NPCTs
will require research teams to collaborate synergistically
across disciplines. The anticipated benefit of combining the
rigorous and trans-disciplinary approaches referenced herein
increases the likelihood that, in the many instances where the
outcome of a NPCT does not signal a change in practice, the
trial will nevertheless have provided actionable new information, for example, about NP metabolism or the target biology.
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ENDNOTES
a

Per the 2014 NIH guidance, a clinical trial is defined here as a research
study in which one or more human subjects are prospectively assigned
to one or more interventions (which may include placebo or other control) to evaluate the effects of those interventions on health-related
biomedical or behavioral outcomes (https://grants.nih.gov/policy/clini
cal-trials/definition.htm).

b

Traditional medical systems are defined by the WHO, in the WHO
Global Report on Traditional and Complementary Medicine 2019 (https
://apps.who.int/iris/bitstream/handle/10665/312342/9789241515436eng.pdf?ua=1) as “the sum total of the knowledge, skill and practices
based on the theories, beliefs and experiences indigenous to different
cultures, whether explicable or not, used in the maintenance of health as
well as in the prevention, diagnosis, improvement or treatment of physical and mental illness.”
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